Frontlight ResearchEarly access
WithdrawnPhase 4
Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT
Key facts
- Who runs it
- Tuen Mun Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 29 Sept 2026
- Ended
- 29 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- recombinant subunit herpes zoster vaccine
- Record updated
- 1 October 2026
- Why it stopped
- lack of funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Patients with a diagnosis of rheumatic or immune-mediated diseases eg. SLE, RA, PSA, SpA, inflammatory myopathies, ANCA-related and large vessel vasculitides
- Age ≥18 years
- Stable or reducing doses of any the following immunosuppressive regimens within 4 weeks of study entry:; Prednisolone ≥20mg/kg/day ± mycophenolate mofetil, azathioprine or the calcineurin inhibitors; Cyclophosphamide (intravenous pulses or daily oral); B-cell depleting biological agents and their biosimilars eg. belimumab, anti-CD20 agents (next scheduled dose should be arranged to at least 12 weeks after study entry for rituximab or obinutuzumab); Anti-TNFα biological agents and their biosimilars eg. infliximab, etanercept, adalimumab, golimumab, certolizumab; Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab; Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab; The JAK inhibitors eg. tofacitinib, baricitinib, upadacitinib
- Female patients with reproductive potential are allowed to participate in this study provided that they are willing to practice contraception for until at least 12 months after vaccination
- Willing to comply with all study procedures
Who cannot take part
- Active infection, including upper respiratory tract infection
- Active HZ infection
- Active untreated tuberculosis
- HIV infection
- History of HZ or varicella vaccination in the past
- History of allergy to any vaccines
- Patients who are pregnant or plan to become pregnancy within one year of study entry
- Lactating women
- Patients who cannot give a written consent (mentally incapable or illiterate)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies
The 2 groups in the trial
- vaccineExisting treatment, for comparison
Shingrix vaccine
Treatment: recombinant subunit herpes zoster vaccine
- placeboPlacebo, for comparison
normal saline injection (0.5mL)
Treatment: recombinant subunit herpes zoster vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial
- Record updated
- 1 October 2026